Dementia: A timeless challenge for humanity that can affect anyone who lives long enough.
Precious memories fade, and tasks we once took for granted become ever harder.
Treatment options remain limited, leaving families emotionally drained.
But all that could change. We’re on the verge of a breakthrough.
Suppressing the progression of dementia is about offering hope. Not just for over 50 million people living with dementia today, but for future generations too.
We’re striving for a future where dementia is defeated, benefiting all of humanity.
Our mission drives us to develop a new treatment, whatever it takes.
With decades of research insights and extensive drug discovery experience, we’re a team of professionals committed to making dementia treatment a reality.
We are Neusignal Therapeutics.
We’re developing NTX-083, a promising drug candidate for treating Alzheimer’s disease (AD). Here, we introduce the history of its development, our research achievements, and our pipeline.
Our company and team, united under the mission: “Defeat dementia for a better tomorrow.”
For inquiries, contact us here.
We welcome questions about research, collaboration opportunities, media requests, and more. We look forward to hearing from you.